Four details:
1. Under the partnership, Avera Cancer Institute will use Sema4’s health intelligence platform to collect and integrate clinical and genomic data supporting cancer research and clinical care at Avera.
2. Sema4, which went public in July under a $500 million merger deal with special purpose acquisition company CM Life Sciences, identifies flags in large population health datasets to help physicians make more informed decisions for treatments.
3. Sema4 will provide Avera with predictive disease network models and tools that will let the health system’s physicians easily search for cohorts of patients based on clinical criteria, view patients’ treatment histories and better match patients to clinical trials.
4. The partnership will also let more Avera patients receive genomic testing earlier in their disease timeline through Sema4’s genetic sequencing platforms.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
